Ventyx Biosciences, Inc. issued a press release announcing pipeline updates and clinical data for its NLRP3 inhibitor portfolio, along with an update on the company's cash runway based on pipeline reprioritization and recent PIPE financing.
AI Assistant
VENTYX BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.